164 related articles for article (PubMed ID: 36246507)
1. Therapeutic effects of TP5, a Cdk5/p25 inhibitor, in
Tran J; Taylor SKB; Gupta A; Amin N; Pant H; Gupta BP; Mishra RK
Curr Res Neurobiol; 2021; 2():100006. PubMed ID: 36246507
[TBL] [Abstract][Full Text] [Related]
2. TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease.
Binukumar BK; Pant HC
Neural Regen Res; 2016 May; 11(5):698-701. PubMed ID: 27335538
[TBL] [Abstract][Full Text] [Related]
3. Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease.
Binukumar BK; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
Mol Biol Cell; 2015 Dec; 26(24):4478-91. PubMed ID: 26399293
[TBL] [Abstract][Full Text] [Related]
4. TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive CDK5/p25 for the Treatment of Colorectal Carcinoma.
Amin N; Wang H; Song Q; Bhaskar M; Yadav SP; Gilbert MR; Pant H; Tabouret E; Zhuang Z
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511490
[TBL] [Abstract][Full Text] [Related]
5. Cdk5/p25 specific inhibitory peptide TFP5 rescues the loss of dopaminergic neurons in a sub-acute MPTP induced PD mouse model.
Zhang Q; Xie H; Ji Z; He R; Xu M; He Y; Huang J; Pan S; Hu Y
Neurosci Lett; 2016 Oct; 632():1-7. PubMed ID: 27542341
[TBL] [Abstract][Full Text] [Related]
6. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma.
Tabouret E; Wang H; Amin N; Jung J; Appay R; Cui J; Song Q; Cardone A; Park DM; Gilbert MR; Pant H; Zhuang Z
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708903
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
Kanagaraj N; Beiping H; Dheen ST; Tay SS
Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
[TBL] [Abstract][Full Text] [Related]
8. Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.
He R; Huang W; Huang Y; Xu M; Song P; Huang Y; Xie H; Hu Y
Front Aging Neurosci; 2018; 10():162. PubMed ID: 29910724
[TBL] [Abstract][Full Text] [Related]
9. A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.
Zheng YL; Amin ND; Hu YF; Rudrabhatla P; Shukla V; Kanungo J; Kesavapany S; Grant P; Albers W; Pant HC
J Biol Chem; 2010 Oct; 285(44):34202-12. PubMed ID: 20720012
[TBL] [Abstract][Full Text] [Related]
10. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2.
Smith PD; Mount MP; Shree R; Callaghan S; Slack RS; Anisman H; Vincent I; Wang X; Mao Z; Park DS
J Neurosci; 2006 Jan; 26(2):440-7. PubMed ID: 16407541
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5.
Paoletti P; Vila I; Rifé M; Lizcano JM; Alberch J; Ginés S
J Neurosci; 2008 Oct; 28(40):10090-101. PubMed ID: 18829967
[TBL] [Abstract][Full Text] [Related]
12. CDK4 and CDK5 Inhibition Have Comparable Mild Hypothermia Effects in Preventing Drp1-Dependent Mitochondrial Fission and Neuron Death Induced by MPP
Yang SH; Huang CY; Hsieh CY; Chuang JI
Mol Neurobiol; 2020 Oct; 57(10):4090-4105. PubMed ID: 32666227
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase 5--a neuronal killer?
Guo Q
Sci Aging Knowledge Environ; 2003 Dec; 2003(50):pe36. PubMed ID: 14681576
[TBL] [Abstract][Full Text] [Related]
14. The role of CDK5/P25 formation/inhibition in neurodegeneration.
Camins A; Verdaguer E; Folch J; Canudas AM; Pallàs M
Drug News Perspect; 2006 Oct; 19(8):453-60. PubMed ID: 17160145
[TBL] [Abstract][Full Text] [Related]
15. Huang Lian Jie Du Tang attenuates paraquat-induced mitophagy in human SH-SY5Y cells: A traditional decoction with a novel therapeutic potential in treating Parkinson's disease.
Lee IJ; Chao CY; Yang YC; Cheng JJ; Huang CL; Chiou CT; Huang HT; Kuo YH; Huang NK
Biomed Pharmacother; 2021 Feb; 134():111170. PubMed ID: 33383311
[TBL] [Abstract][Full Text] [Related]
16. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
Kesavapany S; Zheng YL; Amin N; Pant HC
Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
[TBL] [Abstract][Full Text] [Related]
17. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.
Sun LH; Ban T; Liu CD; Chen QX; Wang X; Yan ML; Hu XL; Su XL; Bao YN; Sun LL; Zhao LJ; Pei SC; Jiang XM; Zong DK; Ai J
J Neurochem; 2015 Sep; 134(6):1139-51. PubMed ID: 26118667
[TBL] [Abstract][Full Text] [Related]
18. Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease.
Allnutt AB; Waters AK; Kesari S; Yenugonda VM
ACS Chem Neurosci; 2020 May; 11(9):1218-1230. PubMed ID: 32286796
[TBL] [Abstract][Full Text] [Related]
19. Maackiain Ameliorates 6-Hydroxydopamine and
Tsai RT; Tsai CW; Liu SP; Gao JX; Kuo YH; Chao PM; Hung HS; Shyu WC; Lin SZ; Fu RH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32585871
[TBL] [Abstract][Full Text] [Related]
20. Calpain-2/p35-p25/Cdk5 pathway is involved in the neuronal apoptosis induced by polybrominated diphenyl ether-153.
Zhang H; Chang L; Zhang H; Nie J; Zhang Z; Yang X; Vuong AM; Wang Z; Chen A; Niu Q
Toxicol Lett; 2017 Aug; 277():41-53. PubMed ID: 28559121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
